Calcimedica announces pricing of public offering of common stock

La jolla, calif. , oct. 30, 2024 /prnewswire/ -- calcimedica, inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium ("crac") channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced the pricing of an underwritten public offering of 2,720,000 shares of its common stock at a price to the public of $3.75 per share.
CALC Ratings Summary
CALC Quant Ranking